Centrum 7/6  banner

FDA Safety Communication does not impact BD syringes

Print Friendly, PDF & Email

FRANKLIN LAKES, N.J. — BD (Becton, Dickinson and Co.) has issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:

Eric Borin, president of BD Medication Delivery Solutions said, “The FDA safety notice does not apply to any BD syringes. Essentially all plastic syringes BD provides to the U.S. health care system are manufactured in the United States in Nebraska and Connecticut. BD remains committed to supporting the U.S. health care system and is ready to increase production to help supply those providers who currently purchase syringes impacted by the FDA communication.

“Ensuring the safety and quality of our products is the top priority at BD. We have been supporting health care needs with needles and syringes since the inception of our company in 1897 and have provided these products to the U.S. health care system through two world wars, the Polio vaccination trials and multiple pandemics — most recently manufacturing 2 billion additional syringes for COVID-19 vaccinations. BD stands ready to deploy our capacity to support the U.S. health care system and patients.”


Comments are closed.